Key takeaways for Wyoming
- • Wegovy is the FIRST weight-loss GLP-1 with an MACE-reduction indication (Mar 2024).
- • Ozempic carries a CV indication in T2D adults with established CVD.
- • SELECT showed 20% MACE reduction over roughly 3.3 years on Wegovy.
- • Wyoming Medicaid coverage rules apply for Cardiovascular Risk Reduction patients in Wyoming — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Cardiovascular Risk Reduction
Multiple GLP-1 drugs have FDA-approved cardiovascular indications. In March 2024, Wegovy became the first weight-loss drug approved to reduce risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal MI, non-fatal stroke — in adults with established CVD and obesity/overweight. Ozempic carries an MACE-reduction indication in T2D adults with established CVD. Evidence grade: A (large outcomes trials). Trulicity (dulaglutide) has a similar T2D CV indication via REWIND. These indications are based on dedicated CV outcomes trials, not extrapolation.
Wyoming-specific context
Wyoming has telehealth access concentrated in Cheyenne, Casper, Laramie metros, with additional reach to Gillette and Rock Springs. Wyoming Medical Center, Cheyenne Regional Medical Center is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.wyo.gov.
Wyomingtelehealth & pricing rules
- • Wyoming permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Wyoming allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Wyoming: ~$251/mo (compounded options often lower, brand higher).